| HTG Molecular Diagnostics is a commercial stage RNA platform-based life sciences company focused on developing medicine. Co.'s product and service solutions are based on its digital HTG EdgeSeq technology that enables RNA profiling using a small amount of biological sample, in liquid or solid forms. Co. markets proprietary molecular profiling panels targeting late stage drug development programs with potential breakthrough therapies, such as immuno-oncology. Co.'s marketed panels include: HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq Precision Immuno-Oncology Panel; HTG Lung Fusions Assay;HTG Autoimmune Panel; HTG EdgeSeq Immuno-Oncology Assay; and HTG Mouse mRNA Tumor Response Panel. We show 32 historical shares outstanding datapoints in our HTGM shares outstanding history coverage, used to compute HTGM market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HTGM market cap history over the course of time is important for investors
interested in comparing HTGM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HTGM versus a peer is one thing; comparing
HTGM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HTGM can fluctuate over the course of history.
With this page we aim to empower investors researching HTGM by allowing them to research the HTGM market cap history.